Aquestive Therapeutics financials
$4.67−1.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.8M | $14.4M | $13.0M | $12.8M | $10.0M | $8.7M | $11.9M | $13.5M | $20.1M | $12.1M | $13.2M | $13.0M |
| Gross profit | $9.8M | $11.0M | $7.2M | $8.3M | $5.4M | $5.1M | $7.3M | $9.1M | $15.6M | $7.7M | $8.5M | $8.2M |
| Gross margin | 70.9% | 76.0% | 55.2% | 64.8% | 54.4% | 58.1% | 61.9% | 67.2% | 77.5% | 63.6% | 64.6% | 63.1% |
| Operating income | -$8.2M | -$4.2M | -$30.3M | -$12.9M | -$11.4M | -$19.4M | -$15.0M | -$9.6M | $55.0K | -$9.0M | -$3.9M | -$2.4M |
| Net income | -$22.9M | -$8.1M | -$31.9M | -$15.4M | -$13.5M | -$22.9M | -$17.1M | -$11.5M | -$2.7M | -$12.8M | -$8.1M | -$2.0M |
| Net margin | −165.5% | −55.8% | −244.8% | −120.6% | −135.4% | −263.0% | −143.7% | −85.0% | −13.7% | −106.4% | −61.4% | −15.7% |
| Diluted EPS | $-0.18 | $-0.07 | $-0.26 | $-0.14 | $-0.14 | $-0.24 | $-0.19 | $-0.13 | $-0.03 | $-0.17 | $-0.16 | $-0.03 |
| EBITDA | -$8.1M | -$4.1M | -$30.1M | -$12.8M | -$11.2M | -$19.2M | -$14.8M | -$9.5M | $260.0K | -$8.8M | -$3.4M | -$2.1M |
| Operating cash flow | -$9.4M | -$14.8M | -$8.5M | -$12.6M | -$7.9M | -$23.4M | -$6.5M | -$11.9M | -$7.0M | -$10.4M | -$4.9M | -$2.3M |
| Free cash flow | -$9.7M | -$14.9M | -$8.6M | -$12.9M | -$8.0M | -$23.5M | -$6.5M | -$12.0M | -$7.0M | -$10.4M | -$5.0M | -$2.5M |
| Diluted shares | 125.0M | 122.6M | 122.3M | 110.6M | 99.3M | 95.5M | 91.3M | 91.1M | 90.9M | 73.6M | 49.2M | 64.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $98.5M | $110.7M | $121.2M | $129.1M | $60.5M | $68.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $50.7M | $38.8M | $37.5M | $60.8M | $58.1M | $33.8M |
| Total assets | $132.1M | $141.1M | $160.4M | $163.6M | $93.7M | $102.2M |
| Total liabilities | $188.7M | $175.2M | $194.1M | $167.7M | $166.3M | $160.9M |
| Shareholders' equity | -$56.6M | -$34.1M | -$33.7M | -$4.1M | -$72.6M | -$58.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology